Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas

Keyphrases

• Neurofibromatosis Type I 100%
• Neurofibromatosis Type 1 (NF-1) 100%
• Treatment Decisions 100%
• MEK Inhibitor (MEKi) 100%
• Plexiform Neurofibroma 100%
• Pediatric Patients 20%
• Medical Therapy 20%
• Medical Treatment 20%
• Selumetinib 20%
• Treatment Options 10%
• Targeted Therapy 10%
• Improved Outcomes 10%
• Tumor Volume 10%
• Treatment Strategy 10%
• Tyrosine Kinase Inhibitor 10%
• Negative Regulator 10%
• Phase II Trial 10%
• Surgical Resection 10%
• Complex Disease 10%
• Range of Motion 10%
• Gene Variants 10%
• Cabozantinib 10%
• Neurofibromin 10%
• Multidisciplinary Team 10%
• Heterogeneous Disease 10%
• Tumor-associated 10%
• MEK1 10%
• Binimetinib 10%
• Tumor Predisposition Syndrome 10%
• Patient-reported Outcomes 10%
• Quality of Life Improvement 10%
• Patient Preference 10%
• Single Treatment 10%
• Trametinib 10%
• Multiple Aspects 10%
• Peripheral Nerve Sheath Tumor 10%
• Watchful Waiting 10%
• Family Decision 10%
• Treatment Pathways 10%
• Accessible Treatment 10%
• Clinical Decision-making 10%
• Morbidity Outcomes 10%

Medicine and Dentistry

• Neurofibromatosis Type I 100%
• MEK Inhibitor 100%
• Plexiform Neurofibroma 100%
• Neoplasm 30%
• Pediatrics Patient 20%
• Morbidity 20%
• Selumetinib 20%
• Diseases 20%
• Targeted Therapy 10%
• Disease Predisposition 10%
• Clinician 10%
• Clinical Study 10%
• Quality of Life 10%
• Cabozantinib 10%
• Clinical Decision Making 10%
• Range of Motion 10%
• Trametinib 10%
• Tyrosine-Kinase Inhibitor 10%
• Nerve Sheath Tumor 10%
• Watchful Waiting 10%
• Binimetinib 10%
• Peripheral Nerve 10%
• Treatment Option 10%
• Patient-Reported Outcome 10%
• Genetics 10%